Manchester Pharmaceuticals, Inc. Announces Availability of Chenodal(TM)

FORT COLLINS, Colo., Dec. 14 /PRNewswire/ -- Manchester Pharmaceuticals, Inc.(TM) announced today the availability of Chenodal(TM) 250 mg (chenodiol tablets). On October 22, 2009, the US Food and Drug Administration (FDA) approved Chenodal, an important therapy for patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

"The commercial availability of Chenodal now provides doctors and their patients with a chenodiol product that meets all FDA requirements for product integrity, quality, safety and effectiveness," commented Lloyd Glenn, Manchester's President.

Manchester Pharmaceuticals, Inc.


Back to news